Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations
Authors:
- C. SchneiderCSC. Schneider
- S. S. JickSJS. S. Jick
- C. R. MeierCMC. R. Meier
- 11 November 2009
- journal article
- research article
- Published by Taylor & Francis in Climacteric
- Vol. 12 (6) , 514-524
Abstract
Objectives Use of postmenopausal hormone replacement therapy (HRT) has been associated with an elevated risk of gynecological cancers. There is evidence that the effect differs with the type of hormone used. Dydrogesterone is pharmacologically very similar to progesterone. Methods We used the UK-based General Practice Research Database (GPRD) to conduct a follow-up study with a nested case–control analysis. We assessed and compared the risk of developing breast, ovarian, endometrial/uterine or cervical cancer in estradiol/dydrogesterone (E/D) users, users of other HRT, or non-users of HRT. Results The breast cancer incidence rates were 2.41 (95% confidence interval (CI) 1.81–3.15), 3.28 (95% CI 3.01–3.55) and 3.16 (95% CI 2.92–3.42) per 1000 person-years for E/D users, users of other HRT or non-users, respectively. In a direct comparison, the breast cancer risk for E/D users was lower than for users of other HRT (odds ratio 0.76, 95% CI 0.56–1.05). The incidence rates of other gynecological cancers were similar or also slightly lower for E/D users than for users of other HRT. Conclusion This study provides evidence that the risk of developing gynecological cancers with E/D use of several months to a few years is similar to the risks of developing gynecological cancer without HRT or use of other HRT.Keywords
This publication has 29 references indexed in Scilit:
- Changes in utilisation of hormone replacement therapy in Australia following publication of the findings of the Women's Health InitiativePharmacoepidemiology and Drug Safety, 2008
- Long-term impact of the women’s health initiative on HRTArchives of Gynecology and Obstetrics, 2007
- Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since MenopauseJAMA, 2007
- Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic ProceduresThe Women's Health Initiative Randomized TrialJAMA, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Cardiovascular Disease Outcomes During 6.8 Years of Hormone TherapyJAMA, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal womenThe Lancet, 1997
- Estrogens, Progesterone, and Endometrial CancerEpidemiology, 1993